{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:54:11Z","timestamp":1791564851959,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jns.2026.126201","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:32:58Z","timestamp":1791243178000},"page":"126201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Valproate use in low- and middle-income countries: Balancing reproductive safety, seizure control, and access to safer antiseizure medicines"],"prefix":"10.1016","volume":"491","author":[{"given":"H.M.M.T.B.","family":"Herath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameera","family":"Senanayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4209-1057","authenticated-orcid":false,"given":"Akhila Rakshitha","family":"Wimalasundera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inuka K.","family":"Gooneratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2026.126201_bb0005","series-title":"Epilepsy","author":"World Health O","year":"2024"},{"key":"10.1016\/j.jns.2026.126201_bb0010","series-title":"Epilepsy: A Public Health Imperative","author":"World Health O","year":"2019"},{"key":"10.1016\/j.jns.2026.126201_bb0015","series-title":"Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022\u20132031","author":"World Health O","year":"2023"},{"key":"10.1016\/j.jns.2026.126201_bb0020","series-title":"Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022\u20132031: Implementation Toolkit","author":"World Health O","year":"2024"},{"key":"10.1016\/j.jns.2026.126201_bb0025","series-title":"Antiseizure Medicines for Management of Epilepsy in Adults and Children","author":"World Health O","year":"2023"},{"key":"10.1016\/j.jns.2026.126201_bb0030","series-title":"Epilepsies in Children, Young People and Adults. NICE Guideline NG217","author":"National Institute for H, Care E","year":"2022"},{"issue":"7","key":"10.1016\/j.jns.2026.126201_bb0035","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/epi.13021","article-title":"Valproate in the treatment of epilepsy in girls and women of childbearing potential","volume":"56","author":"Tomson","year":"2015","journal-title":"Epilepsia"},{"issue":"9848","key":"10.1016\/j.jns.2026.126201_bb0040","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0140-6736(12)61381-6","article-title":"Epilepsy in poor regions of the world","volume":"380","author":"Newton","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2026.126201_bb0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.seizure.2018.02.002","article-title":"Epidemiological profile of epilepsy in low income populations","volume":"56","author":"Espinosa-Jovel","year":"2018","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.jns.2026.126201_bb0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.25259\/JNRP_527_2023","article-title":"Epilepsy care and outcome in low- and middle-income countries: a scoping review","volume":"15","author":"Bankole","year":"2024","journal-title":"J. Neurosci. Rural. Pract."},{"issue":"9566","key":"10.1016\/j.jns.2026.126201_bb0055","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"10282","key":"10.1016\/j.jns.2026.126201_bb0060","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","article-title":"The SANAD II study of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jns.2026.126201_bb0065","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa0902014","article-title":"Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy","volume":"362","author":"Glauser","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2026.126201_bb0070","author":"World Health O"},{"issue":"11","key":"10.1016\/j.jns.2026.126201_bb0075","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209279","article-title":"Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication: practice guideline from the AAN, AES, and SMFM","volume":"102","author":"Pack","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126201_bb0080","author":"American Epilepsy S"},{"key":"10.1016\/j.jns.2026.126201_bb0085","author":"European Medicines A"},{"key":"10.1016\/j.jns.2026.126201_bb0090","author":"Medicines, Healthcare products Regulatory A"},{"issue":"5","key":"10.1016\/j.jns.2026.126201_bb0095","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamaneurol.2024.0258","article-title":"Risk of major congenital malformations and exposure to antiseizure medication monotherapy","volume":"81","author":"Battino","year":"2024","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.jns.2026.126201_bb0100","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","article-title":"Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry","volume":"10","author":"Tomson","year":"2011","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.126201_bb0105","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years: a prospective observational study","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol."},{"issue":"16","key":"10.1016\/j.jns.2026.126201_bb0110","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jns.2026.126201_bb0115","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/epi.18294","article-title":"Seizure control and pregnancy outcomes in Chinese women with epilepsy: a prospective multicenter cohort study","volume":"66","author":"Hao","year":"2025","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.jns.2026.126201_bb0120","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/epi.13632","article-title":"Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India","volume":"58","author":"Thomas","year":"2017","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.jns.2026.126201_bb0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40264-020-00987-4","article-title":"Understanding and responding to prescribing patterns of sodium valproate-containing medicines in pregnant women and women of childbearing age in Western cape, South Africa","volume":"44","author":"Mehta","year":"2020","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.jns.2026.126201_bb0130","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurology."},{"issue":"0","key":"10.1016\/j.jns.2026.126201_bb0135","article-title":"The valproate prescription pattern for female mental healthcare users of reproductive age","volume":"30","author":"Gasa","year":"2024","journal-title":"S. Afr. J. Psychiatry"},{"key":"10.1016\/j.jns.2026.126201_bb0140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.seizure.2023.04.009","article-title":"Minimum effective sodium valproate dose in genetic generalized epilepsies","volume":"108","author":"Marques","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.jns.2026.126201_bb0145","series-title":"Topiramate: Introduction of New Safety Measures, Including a Pregnancy Prevention Programme","author":"Medicines, Healthcare Pproducts Regulatory a","year":"2024"},{"issue":"5","key":"10.1016\/j.jns.2026.126201_bb0150","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1528-1167.2005.52704.x","article-title":"Cost-effectiveness of first-line antiepileptic drug treatments in the developing world: a population-level analysis","volume":"46","author":"Chisholm","year":"2005","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.jns.2026.126201_bb0155","doi-asserted-by":"crossref","first-page":"674","DOI":"10.4103\/aian.AIAN_264_19","article-title":"Antiepileptic drug prices, availability and affordability in a resource-limited setting","volume":"23","author":"Singh","year":"2020","journal-title":"Ann. Indian Acad. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2026.126201_bb0160","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/epi4.12432","article-title":"Availability, affordability, and quality of essential antiepileptic drugs in Lao PDR","volume":"5","author":"Sengxeu","year":"2020","journal-title":"Epilepsia Open."},{"issue":"3","key":"10.1016\/j.jns.2026.126201_bb0165","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/epi4.12514","article-title":"Availability, affordability, and quality of essential anti-seizure medication in Cambodia","volume":"6","author":"Sengxeu","year":"2021","journal-title":"Epilepsia Open."},{"issue":"8","key":"10.1016\/j.jns.2026.126201_bb0170","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/epi.17668","article-title":"Affordability of newer antiseizure medications in Asian resource-limited countries","volume":"64","author":"Fong","year":"2023","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.jns.2026.126201_bb0175","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1528-1167.2012.03446.x","article-title":"Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries","volume":"53","author":"Cameron","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2026.126201_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103558","article-title":"Antiseizure medications consumption in 73 countries and regions from 2012 to 2022: a longitudinal trend study","volume":"89","author":"Chan","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"7","key":"10.1016\/j.jns.2026.126201_bb0185","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1528-1157.1999.tb00807.x","article-title":"Lamotrigine-associated rash: risk\/benefit considerations in adults and children","volume":"40","author":"Guberman","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2026.126201_bb0190","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","article-title":"Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy","volume":"76","author":"Chen","year":"2017","journal-title":"Epilepsy Behav."},{"issue":"3","key":"10.1016\/j.jns.2026.126201_bb0195","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/epi.13294","article-title":"Health and economic benefits of public financing of epilepsy treatment in India: an agent-based simulation model","volume":"57","author":"Megiddo","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2026.126201_bb0200","series-title":"WHO Model List of Essential Medicines \u2013 23rd List, 2023","author":"World Health O","year":"2023"},{"key":"10.1016\/j.jns.2026.126201_bb0205","series-title":"Epilepsy Management at Primary Health Level in Rural China: WHO\/ILAE\/IBE a Global Campaign against Epilepsy Demonstration Project","author":"World Health O","year":"2009"},{"issue":"3","key":"10.1016\/j.jns.2026.126201_bb0210","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1528-1167.2007.01529_2.x","article-title":"Primary care treatment of epilepsy with phenobarbital in rural China: cost-outcome analysis from the WHO\/ILAE\/IBE global campaign against epilepsy demonstration project","volume":"49","author":"Ding","year":"2008","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.jns.2026.126201_bb0215","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/epi.14445","article-title":"Quality of antiepileptic drugs in sub-Saharan Africa: a study in Gabon, Kenya, and Madagascar","volume":"59","author":"Jost","year":"2018","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.jns.2026.126201_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209985","article-title":"Women\u2019s reproductive health decision-making: a multi-country analysis of demographic and health surveys in sub-Saharan Africa","volume":"14","author":"Darteh","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jns.2026.126201_bb0225","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2023-000760","article-title":"Use of sodium valproate and other antiseizure drug treatments in England and Wales: quantitative analysis of nationwide linked electronic health records","volume":"3","author":"Dale","year":"2024","journal-title":"BMJ Med."},{"issue":"2","key":"10.1016\/j.jns.2026.126201_bb0230","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2023-000433","article-title":"Valproate pregnancy prevention scheme: what are the barriers to enrolling patients and how do we meet them?","volume":"5","author":"Watila","year":"2023","journal-title":"BMJ Neurol. Open"},{"issue":"4","key":"10.1016\/j.jns.2026.126201_bb0235","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(18)30454-X","article-title":"Global, regional, and national burden of epilepsy, 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"18","author":"Beghi","year":"2019","journal-title":"Lancet Neurology."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:16:54Z","timestamp":1791562614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26004831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":47,"alternative-id":["S0022510X26004831"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.126201","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valproate use in low- and middle-income countries: Balancing reproductive safety, seizure control, and access to safer antiseizure medicines","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.126201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126201"}}